Abstract: Objective：To evaluate the value of gestrinone in the treatment of endometriosis （EMs）. Methods：We searched OVID, MEDLINE and CNKI for RCTs. This meta-analysis is performed based on “Cochrane Handbook for Systematic Reviews of Interventions”. Results：Gestrinone has better curative effect compared with marvelon （RR=8.270，95%CI：1.046-65.384），but its efficiency is inferior to GnRHa （RR=0.888，95%CI：0.845-0.933），danazol （RR=1.043，95%CI：0.949-1.146），mifepristone （RR=0.972，95%CI：0.943-1.003） and traditional Chinese medicine （RR=0.954，95%CI：0.905-1.006） show no difference from gestrinone in efficiency. Gestrinone and mifepristone （RR=0.913，95%CI：0.730-1.140） have equal pregnancy rate，but more women get pregnant after treated by GnRHa when compared with that by gestrinone （RR=0.792，95%CI：0.657-0.954）. Gestrinone shows a higher incidence of side effect （liver dysfunction） than mifepristone （RR=1.865，95%CI：1.453-2.394） and marvelon （RR=8.270，95%CI：1.046-65.384），but there is no difference when compared with GnRHa （RR=1.308，95%CI：0.965-1.772）. The AFS scores of two dosage regimens of gestrinone are the same （SMD=0.185，95%CI：-0.491-0.861）. Conclusions：As a second-line drug for treating EMs，the effeciency of gestrinone is inferior to GnRHa. Increasing the dosage shows no improvement on efficiency. It′s still an option when the side effects are tolerable.

Key words: Endometriosis, Gestrinone, Gonadotropin-releasing hormone, Desogestrel, Medicine, Chinese traditional, Mifepristone, Dysmenorrhea, Pelvic pain, Pregnancy rate